Zenkuda and Tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD
Zenkuda Demonstrates a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-week Dosing Interval in wAMD
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Wet Age-related Macular Degeneration | First-time One-year Primary Efficacy and Safety Outcomes of the Phase 3 DAYBREAK Study